It’s a struggle that comic-book fans know well. Ordinary people, bestowed with super powers from a spider bite or gamma rays, struggle to harness their own abilities. T cells, key soldiers of the immune system, are wrestling with new-found super powers, too. Certain T cells hunt down invasive viruses, bacteria, and the body’s own bad … Continue reading “Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed?”
Category: San Diego
Scott Gottlieb On Tap to Lead FDA, and Biopharma Exhales
[Updated 3/12/17 with more comments, see below] The Trump administration has nominated Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon. The 44-year-old Gottlieb is a physician, a venture partner at New Enterprise Associates, and was also the deputy … Continue reading “Scott Gottlieb On Tap to Lead FDA, and Biopharma Exhales”
Tocagen Plans IPO to Finance Trials of Gene Therapy in Brain Cancer
[Corrected 3/10/17, 3:27 pm. See below] Gene therapy developer Tocagen is preparing an initial public stock offering to finance clinical trials of its experimental treatment for a form of brain cancer. The San Diego-based biotech filed the paperwork Thursday for an IPO that could raise up to $86 million—a figure likely to change as the … Continue reading “Tocagen Plans IPO to Finance Trials of Gene Therapy in Brain Cancer”
Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More
We’ll start the roundup in Washington DC. The repeal of the Affordable Care Act, also known as Obamacare, began on the first day of the Trump administration. This week, the “replace” phase began with a Republican plan championed by House Speaker Paul Ryan (R-WI). President Trump backed it, too, but a lot of Republicans have … Continue reading “Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More”
Will Driverless Cars Ever Yield Profits for Uber and Lyft?
Uber has suffered a series of troubles early this year, from sexual harassment claims by a former staff engineer to an intellectual property theft lawsuit by Google unit Waymo. But Uber’s most longstanding, recurrent, and core problem stems from its relationship with its contract drivers. It’s not surprising that Uber is seeking an escape from … Continue reading “Will Driverless Cars Ever Yield Profits for Uber and Lyft?”
Larry Smarr Drives Innovation as Experimental Patient of the Future
In the years since he basically self-diagnosed his own Crohn’s Disease (before he had symptoms), Larry Smarr has served as a pioneer in the digital transformation of medicine and as an “n of 1” experimental patient in the emerging field of quantified health. Smarr came to San Diego in 2000 as founding director of the … Continue reading “Larry Smarr Drives Innovation as Experimental Patient of the Future”
Toyota and Others Enabling Self-Driving Cars to Talk to Each Other
Drivers have plenty of ways to communicate with their fellow drivers, beyond the basic turn signal. Some methods are nice, like a friendly wave to beckon a merging car into your lane. Others, not so much. We’ve all probably cursed or honked at another driver, or been given the finger. But if driverless cars become … Continue reading “Toyota and Others Enabling Self-Driving Cars to Talk to Each Other”
Immigrants Are the Best of Humanity and the Strength of Our Nation
[Editor’s note: This post was adapted from Mohamad Ali’s speech at a naturalization ceremony at the JFK Library in Boston on March 8, 2017.] My fellow immigrants, buenas tardes, masa-al-khayr, and good afternoon! I am deeply moved by the opportunity to be here today, to share this momentous occasion with you, and to personally return … Continue reading “Immigrants Are the Best of Humanity and the Strength of Our Nation”
Three Ways to Bolster The Innovation Ecosystem for Women
When the topic of encouraging more female leadership in the startup economy arises, discussions usually center on what women entrepreneurs should do differently. How they should present with greater authority, or how they should “dress the part” for their next investor pitch. Put frankly, how they should adopt any manner of different behaviors. I would … Continue reading “Three Ways to Bolster The Innovation Ecosystem for Women”
CureMatch Uses Analytics to Rank Best Options for Cancer Treatment
CureMatch, a San Diego-based healthtech startup, says today it has created a Web-based platform that uses analytic software to help doctors sort through what can be a bewildering array of cancer treatment options. Selecting the right combination of drugs to treat a particular cancer can be one of the biggest challenges that doctors face, according … Continue reading “CureMatch Uses Analytics to Rank Best Options for Cancer Treatment”
Bio Roundup: Healthcare Is Hard, “Slow” FDA, Drugging RNA & More
In an address to Congress this week, President Donald Trump outlined many of his near-term goals, including an overhaul of the Affordable Care Act, also known as Obamacare, even as public opinion has begun to shift in favor of the law. Trump toned down his typical blunderbuss rhetoric, but he had choice words for the … Continue reading “Bio Roundup: Healthcare Is Hard, “Slow” FDA, Drugging RNA & More”
Capital Stockpile Grows as Venture Fund-Raising Hits Recent High
In the venture capital business, a rising tide lifts all boats. That’s the idea, at least. A new report released today by Seattle-based PitchBook shows that U.S. venture firms have plenty of capital to invest in new companies, after 328 venture funds raised a total of $51.6 billion in 2016. That’s a high-water mark for … Continue reading “Capital Stockpile Grows as Venture Fund-Raising Hits Recent High”
Snap Raises $3.4B in IPO, Soaring Trades Set Value Past $20B
Snap, which rose to unicorn status based on a social media app that creates quickly vanishing photos, attracted solid investor interest in an IPO that raised $3.4 billion and sent shares up more than 50 percent above the initial offering price during the first day of trading today. Snap (NYSE: [[ticker:SNAP]]) priced its IPO shares … Continue reading “Snap Raises $3.4B in IPO, Soaring Trades Set Value Past $20B”
Trump and Kalanick: Twin Chief Executives Face Similar Problems
In the rinse-repeat rhythm of Uber’s PR crises, it’s easy to miss that this particular cycle has been a long one. Uber’s latest wave of negative press began in January with a backlash against CEO Travis Kalanick’s role on President Donald Trump’s White House business advisory panel. There’s some irony here, because Trump and Kalanick … Continue reading “Trump and Kalanick: Twin Chief Executives Face Similar Problems”
Human Impact of Innovation Super Saver Special Ends Today!
Time is running out to secure the $99 super saver discount for The Xconomy Forum on Human Impact of Innovation on April 19 in San Diego. The forum will take place at The Illumina Theater at The Alexandria at Torrey Pines. There has been a lot of talk around the importance of studying and understanding … Continue reading “Human Impact of Innovation Super Saver Special Ends Today!”
Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M
Last month, Grail publicly spread word of intentions to raise more than $1 billion in an ambitious quest to develop a blood test that can diagnose and detect cancer at its earliest stages. Today, the Menlo Park, CA, startup has revealed the crop of drugmakers and others it has secured to fund the effort. Grail … Continue reading “Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M”
Former FDA Commissioners Califf, McClellan Talk Healthcare’s Future
The top spot at the FDA remains vacant, and the change in presidential power has some healthcare observers wondering about possible changes for the regulator. One month removed from serving as FDA commissioner, Robert Califf says the agency can be improved through a combination of precedent, experience, and evidence. Califf, who served less than one … Continue reading “Former FDA Commissioners Califf, McClellan Talk Healthcare’s Future”
Blood Pressure Drug Trial Results Lift La Jolla Pharma Shares
La Jolla Pharmaceutical’s experimental drug to treat a deadly blood pressure condition hit its main goal in a Phase 3 clinical trial, boosting the company’s stock price by more than 75 percent on Monday morning. San Diego-based La Jolla (NASDAQ: [[ticker:LJPC]]) is studying its drug LJPC-501 in patients who have dangerously low blood pressure, which can … Continue reading “Blood Pressure Drug Trial Results Lift La Jolla Pharma Shares”
Bio Roundup: Trump Backlash, Verdine Plans, Sarepta Sale & More
A short week makes for a shorter roundup. As we’ve come to expect, however, there was no dearth of health and life-sciences news from Washington, D.C. A bipartisan group of Congress members who oversee health policy countered President Donald Trump’s encouragement of vaccine skeptics; the real test will be the upcoming budget’s funding of Centers … Continue reading “Bio Roundup: Trump Backlash, Verdine Plans, Sarepta Sale & More”
Sexual Harassment Claims Add to Turbulent Times for Uber
For the second time in less than a month, Uber CEO Travis Kalanick found himself fending off critical questions from his own employees at a Tuesday company-wide meeting. The last time, Kalanick was trying to justify remaining on President Trump’s economic advisory council after Trump issued a sudden travel ban against refugees and people from … Continue reading “Sexual Harassment Claims Add to Turbulent Times for Uber”
Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M
PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company, headquartered in Cranbury, NJ, disclosed this morning that it has raised a $74 million Series B round from Topspin Biotech … Continue reading “Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M”
Amazon, Uber, and Bill Gates’s Robot Tax: An Automation Snapshot
As we gear up for Robo Madness 2017: A.I. Gets Real, our annual robotics and artificial intelligence conference at Google’s offices in Kendall Square, let’s connect a few dots around the topic of automation. In just the past day or two: —Uber has started testing self-driving cars in Tempe, AZ, after having its tests banned … Continue reading “Amazon, Uber, and Bill Gates’s Robot Tax: An Automation Snapshot”
Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking Shares
Cidara Therapeutics is halting work on an experimental topical antifungal drug designed to treat vaginal yeast infections after the compound wasn’t better than the current standard of care in a Phase 2 clinical trial. San Diego-based Cidara (NASDAQ: [[ticker:CDTX]]) said in a statement on Tuesday it will now shift its resources to other compounds in … Continue reading “Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking Shares”
Agtech Accelerator Radicle Recruits Industry Vets to Mentor Startups
Former Sapphire Energy CEO Jason Pyle is one of four agricultural technology veterans who have agreed to advise the startups taking root at Radicle, the San Diego-based accelerator focused on agricultural and food tech ventures. Radicle named Pyle, who is now the CEO of BaseHealth, a Silicon Valley healthtech developer of analytic software, as a … Continue reading “Agtech Accelerator Radicle Recruits Industry Vets to Mentor Startups”
Lumina Foundation Gives Odds For Edtech Innovation Under Trump
[Corrected 2/22/17, 9:35 am. See below.] Bipartisanship hasn’t exactly been the watchword in Washington over the past month as the new Trump administration grapples with stalled nominations, court battles over its travel ban, and investigations of campaign contacts with Russia. But deeply divided politicians may still find some common ground over education policy—in ways that … Continue reading “Lumina Foundation Gives Odds For Edtech Innovation Under Trump”
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More
News may be coming out of Washington, DC, at a breakneck pace, but concrete plans regarding the future of the nation’s healthcare system, the FDA, and the pharmaceutical industry have been much slower to materialize. The consternation about President Donald Trump’s coming pick for FDA commissioner was palpable this week at the BIO CEO & … Continue reading “Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More”
Dermata Secures $10M in Combined Financing for Skin Treatments
[Corrected 2/17/17, 9:41 am to differentiate Silicon Valley Bank’s loan from private investment.] Dermata Therapeutics, a San Diego development-stage biotech advancing new treatments for rosacea, eczema, and related dermatological diseases, said it has secured $5 million in additional funding from private investors and entered into a $5 million credit facility with Silicon Valley Bank. The … Continue reading “Dermata Secures $10M in Combined Financing for Skin Treatments”
Join Us: Xconomy Forum on Innovations with Widespread Human Impact
Over the past 30 years or so, design theorists have promoted the idea of putting humans at the center of the process that innovators use to design everyday things. At the UC San Diego Design Lab, director Don Norman talks about the importance of studying and understanding how people are actually using something—whether it is … Continue reading “Join Us: Xconomy Forum on Innovations with Widespread Human Impact”
With “Go,” Amazon Identifies Another Job It Can Do Better
Early last year, I “fired” talk radio along with NPR’s morning and evening editions. That same day, I “hired” Amazon Audible as my commute companion. It wasn’t a difficult decision. Audible is far better than its predecessors at doing the job I need done as I travel to and from my office – provide on-demand … Continue reading “With “Go,” Amazon Identifies Another Job It Can Do Better”
Fintech VC Backing Dipped 13 Percent in 2016, Mirroring Rest of Tech
The final numbers on 2016 fintech funding deals are in from New York-based research firm and investment database CB Insights, and venture capitalists seem to be cooling on the industry. According to a report released today, financial technology companies around the world attracted $12.7 billion in venture capital across 836 investments last year. That is … Continue reading “Fintech VC Backing Dipped 13 Percent in 2016, Mirroring Rest of Tech”
With $20M, UCSD Spinout Jecure To Press New Attack On NASH
[Updated 2/15/17, 8:10 pm ET. See below.] Liver disease is challenging for doctors because it can develop without symptoms, making diagnosis difficult without removing cells for examination. For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego. Feldstein has been studying the … Continue reading “With $20M, UCSD Spinout Jecure To Press New Attack On NASH”
BIO-Europe Spring
From the event organizer: The eleventh annual BIO-Europe Spring® international partnering conference will be held in Barcelona, Spain March 20–22, 2017 at the CCIB Convention Centre Barcelona. Produced by EBD Group, the event is co-hosted by Biocat, BIOCAT, the organization that coordinates and promotes the health and life sciences sector in Catalonia, and the ACCIO … Continue reading “BIO-Europe Spring”
Dear Tom Price: Bundled Payments Help Patients and Reduce Costs
With all the talk of repealing Barack Obama’s Affordable Care Act (ACA), people have been taking a closer look at what the law has done for our healthcare system. It turns out the ACA is about a lot more than the problematic healthcare marketplaces. There’s the extension of parental insurance coverage to age 26 and … Continue reading “Dear Tom Price: Bundled Payments Help Patients and Reduce Costs”
Senate Confirms Price for HHS, But Stock Deals Still Raise Questions
The Senate confirmed Tom Price as Secretary of the U.S. Department of Health and Human Services early Friday morning by a 52-47 vote that, as expected, fell largely on party lines. Price is an orthopedic surgeon by training who has been a member of Georgia’s congressional delegation since 2004. He will now oversee a department that … Continue reading “Senate Confirms Price for HHS, But Stock Deals Still Raise Questions”
Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More
The biotech community pushed back against President Donald Trump’s order to block travelers and refugees this week, and not much later, a federal court did, too. Patient advocates have scored big wins with recent approvals of rare disease treatments, but they’re not as happy with insurers’ coverage decisions or with Trump’s promises of massive FDA … Continue reading “Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More”
Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation
In the biomedical world, perhaps the biggest question looming over President Donald Trump’s upcoming pick for Food and Drug Administration commissioner is how drastically that person will help roll back FDA regulations. Trump said at last week’s meeting in Washington D.C., with pharmaceutical executives that he wanted to slash FDA rules by 75 to 80 … Continue reading “Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation”
San Francisco Appeals Court Upholds Stay on Trump’s Travel Ban—For Now
The Trump administration’s travel ban will remain on a temporary hold under an order issued today by a federal appeals court in San Francisco, which held that the government had failed to make its case for lifting a stay won through a court challenge by the state of Washington. That means that for the time … Continue reading “San Francisco Appeals Court Upholds Stay on Trump’s Travel Ban—For Now”
Xconomy Is Growing: We Need Great Salespeople in SF, Texas, and NY
Since Xconomy’s founding nearly a decade ago, we have grown from a single bureau in Boston to having editors covering 11 innovation clusters around the United States. And over this time, we have cultivated a reputation for outstanding news coverage and events across high-tech business sectors—from information technology to life sciences and beyond. In the … Continue reading “Xconomy Is Growing: We Need Great Salespeople in SF, Texas, and NY”
Xconomy Forum: Human Impact of Innovation
What are the major innovations that will have the biggest overall impact on humans—on people’s lives, comfort, health, and security—and what role will San Diego play in the advance of these technologies? Xconomy is organizing a half-day forum to explore this theme, focusing on the innovations in the life sciences and technology that appear most … Continue reading “Xconomy Forum: Human Impact of Innovation”
Trump’s Immigration Policies Threaten to Thwart Economic Growth
For the entire staff at Global Detroit, the Executive Orders from President Trump on immigration, refugees, the so-called Muslim ban, and the wall have been devastating and deeply distressing. They challenge our sense of American values and history. Beyond our personal and moral reactions, however, the Executive Orders also may have some impact on the … Continue reading “Trump’s Immigration Policies Threaten to Thwart Economic Growth”
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban
The blowback from U.S. business leaders to President Trump’s travel ban continues—today from a throng of biotech executives. This morning, 165 U.S. biotech leaders have signed a letter voicing “deep concern and opposition” to the order, which bars entry to the U.S. to refugees and immigrants from seven Muslim-majority countries. The Jan. 27 order placed … Continue reading “Biotech Leaders Sign Letter Condemning Trump’s Travel Ban”
Kentucky Biotech CEO’s Message For McConnell: I’ll Be Muslim, Too
President Trump’s order to bar refugees and immigrants from seven Muslim-majority countries is on temporary hold, and a court hearing later today could eventually force a ruling by the U.S. Supreme Court. One of the latest biotech executives to speak out against the ban is in the backyard of Mitch McConnell (R-KY), the top Republican … Continue reading “Kentucky Biotech CEO’s Message For McConnell: I’ll Be Muslim, Too”
As Iraqi Immigrant, Bio CEO Sees Pros and Cons in U.S. Travel Ban
Noori Barka came to California on an H-1B visa in 1986 to work for Santa Monica-based Specialty Laboratories, a medical diagnostics company best known for its clinical testing services. Barka said he had just completed his doctorate in immunology in Belgium, and moved to America with his wife, Evelyn, and his son, David, who was … Continue reading “As Iraqi Immigrant, Bio CEO Sees Pros and Cons in U.S. Travel Ban”
Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins
Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life sciences. Many in biopharma blasted Trump’s order and tried to grapple with its implications. At the same time, a handful of the … Continue reading “Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins”
Drug-Hunting Startup From Scripps Attracts Celgene Alum, $50M Backing
A team of decorated academic chemists in San Diego have been working since 2014 on a biotech startup that aims to find new drugs faster. The company now has a lot of cash in the bank and a well-known biopharma scientist to guide it. Vividion Therapeutics is launching with $50 million pledged from investment firms … Continue reading “Drug-Hunting Startup From Scripps Attracts Celgene Alum, $50M Backing”
Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof
[Updated, 1:57 pm E.T., see below] Another major U.S. health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely watched bellwether in the national debate over drug prices. While UHC’s policy is less restrictive than the one disclosed recently by rival insurer Anthem, UHC … Continue reading “Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof”
Seed-Stage Deals Show Growing Diversity of Agtech Investments
Fundraising is tough for startups but it’s particularly difficult in agriculture, a sector that has fewer firms focused on agtech investments. The dynamics are starting to change, though. A growing number of early-stage agtech startups are raising money and they’re pulling capital from a broader pool of sources, according to a new report from AgFunder, … Continue reading “Seed-Stage Deals Show Growing Diversity of Agtech Investments”
Still No Official Word From Biopharma Groups About Trump Travel Ban
Four days after President Donald Trump issued an order to temporarily ban U.S. entry for people from seven Muslim-majority countries—and for all refugees—the drug industry’s two main lobbying groups have remained silent, even while individual executives in the industry have voiced opposition. The main life science trade group in California has also stayed on the … Continue reading “Still No Official Word From Biopharma Groups About Trump Travel Ban”
Ex-Xerox CTO Vandebroek Named Chief Operating Officer of IBM Research
When I last spoke to Sophie Vandebroek in December, it was for a kind of exit interview as she prepared to leave her longtime job as Xerox’s CTO and head of its worldwide research organization. We went over highlights of her Xerox tenure, her outlook on key technology trends for 2017 and beyond—the Internet of … Continue reading “Ex-Xerox CTO Vandebroek Named Chief Operating Officer of IBM Research”
Cybersecurity in 2017: Goal, Illusion, or Oxymoron?
Here at the (relative) beginning of 2017, we can safely say that the previous year was among the most significant in history from a cybersecurity standpoint. Nation-state actions, in the form of the assumed Russian interference in the U.S. elections (especially the presidential race) and in the leaks of e-mails from the Clinton campaign, dominated … Continue reading “Cybersecurity in 2017: Goal, Illusion, or Oxymoron?”